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Type 1 diabetes (T1D) is a chronic inflammatory autoimmune disease in which T cells destroy insulin-
producing β cells in the pancreas, leading to hyperglycemia. Some T cells directly kill β cells, such as T-
cytotoxic, or indirectly such as T-helper, while others, like regulatory T cells, actually protect them. A 
recent study showed that sodium bicarbonate (SB) exhibited anti-inflammatory activity by affecting 
immune cells other than T cells, implying its potential for the treatment of autoimmune diseases. Since 
SB has never been tested in an experimental mouse model for autoimmunity, we studied the effects of 
SB treatment on the development and severity of T1D, as well as on T cell subsets and T cell function. It 
was hypothesized that SB administration (200 mM, administered via drinking water) would decrease the 
incidence and severity of streptozotocin-induced T1D in 8-week-old C57BL/6 mice by its action on T 
cells. Glucose and body weight measurements were taken biweekly until mice were sacrificed four 
weeks later, and their spleens obtained for analysis of cell counts, viability, T cell proliferation, and 
quantification of T cell subsets by flow cytometry. There were no differences in splenic lymphocyte 
counts and viability between SB-treated and control mice. Although results showed that SB significantly 
decreased glucose levels and delayed diabetes development, it does not seem to affect the frequency of 
T cell populations nor their proliferation capacity. Our results suggest beneficial effects of SB in the 





Type 1 diabetes (T1D) is an autoimmune disease that occurs when inflammatory T cells attack insulin-
producing β cells in the pancreas, which produces a halt in the body’s production of insulin, leading to 
increased blood glucose levels (hyperglycemia). T1D is the second most common autoimmune disease 
among children (Jamshidi et al., 2019). The onset of this disease typically occurs during childhood and 
generates many complications throughout the life of a patient. Early symptoms include polydipsia 
(increased thirst), polyphagia (increased appetite), polyuria (increased urination), weight loss, and fatigue 
(Kahanovitz, Sluss, & Russell, 2017). If untreated, ketoacidosis is likely to occur and more serious 
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symptoms can follow, including cerebral edema, mental confusion, unconsciousness, coma, and death 
(Kahanovitz et al., 2017).  
The incidence of T1D increased at varying rates throughout the 20th century and the same trends 
are being discerned now (Egro, 2013). Egro (2013) stated several hypotheses affirming that an increase in 
T1D incidence could be an implication of increased hygiene over the past decades, viral infections, 
vitamin D deficiency, and even a lack of breastfeeding. The only definitive answer that scientists have 
come up with on T1D etiopathogenesis is that it is a matter of both genetics and environment (Knip & 
Simell, 2012). Without knowing the exact cause of disease, the efforts that have been made toward 
prevention of disease have been futile. Since T1D depends on the over-reactivity of T cells, many 
preventative immunosuppressive approaches are aimed at the destruction of these immune cells 
(Chatenoud, Warncke, & Ziegler, 2012). However, these efforts did not provide expected results. Often 
times the treatments had an overwhelming effect on the immune system, eliminating the cells necessary 
to fight infections and tumors (Chatenoud et al., 2012).  The only current treatment, once T1D is diagnosed, 
is insulin injections, leaving a great need for investigating alternative intervention methods for T1D. 
Sodium bicarbonate (SB) has been used for decades to treat minor health issues, including 
dyspepsia and reflux. It is also implemented in the treatment of serious health complications, including 
metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory 
insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and 
severe primary lactic acidosis (NCBI, n.d.). In a recent study, SB was shown to have in vitro anti-
inflammatory properties, through its action on macrophages (Ray et al., 2018).  One can assume that SB’s 
anti-inflammatory effects on macrophages might also be observed on T cells as well. The same study 
speculated about SB’s potential in prevention of autoimmune diseases, however it had never been tested 
in vivo in an experimental model of autoimmune disease. With T1D being a T cell-mediated autoimmune 
disease, and there being a lack of knowledge on the effects of SB on T cells, further research in this area 
is imperative.  
When studying T cells in T1D, several types of T cells must be considered, as they are crucial in 
the disease’s mechanism of action. Cytotoxic T cells (TC), helper T cells (TH1, TH2, TH17), and regulatory 
T cells (Treg), each of which can be characterized by their particular cell markers (immunophenotypes) 
and the cytokines they release, and can be described as protective or destructive during disease 
development (Cetkovic-Cvrlje, Thinamany, & Bruner., 2017). Contradictory to their names, TH1, TH2, 
and TH17 are not all helpful, nor do they play the same roles in T1D. TH1 release the cytokines interleukin 
(IL)-2 and interferon (IFN)-γ, which are considered to be pathogenic, while TH2 release protective 
cytokines, IL-4 and IL-10 (Kuiper, Moran, Cetkovic-Cvrlje., 2016). TH17 release IL-17, which is also 
considered destructive (Kuiper et al., 2016). Treg do their implied job in regulating the immune system and 
are said to have protective qualities during disease development (Kuiper et al., 2016). C57BL/6J (BL6) 
mice injected by chemical streptozotocin (STZ, Sigma-Aldrich) and NOD/LtJ (NOD) are both acceptable 
model organisms for T1D research. NOD mice spontaneously generate T1D, while BL6 mice must be 
chemically-induced, using 5 low-doses of STZ. Both models exhibit immunological changes during the 
development of T1D, comparable to humans (Cetkovic-Cvrlje et al., 2017).  
The aim of this study was to illuminate antidiabetic properties of SB using a STZ-induced T1D 
mouse model. Since T1D is a T cell-mediated disease, the effects of SB treatment on T cells were closely 
examined. It was hypothesized that SB administration would decrease the incidence and severity of STZ-
induced T1D by its action on T cells in a BL6 mouse model.  
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Mice. BL6 breeding pairs were purchased from Jackson Laboratory in Bar Harbor, ME for continued 
breeding at St. Cloud State University. Mice were housed in NexGen Lo-Profile caging systems in 
temperature- and relative humidity- controlled rooms with a 12-hour light/dark cycle. All mice had 
constant access to casein-based phytosterol-gen-free food and filtered water. St. Cloud State University 
Institutional Animal Care and Use Committee approved all protocols/procedures before experimentation 
began (protocol 5-113).   
Sodium Bicarbonate Preparation. 200 mM concentration of SB (Sigma-Aldrich) drinking water was 
prepared by mixing SB powder with deionized water (Ray et al., 2018). The solution was then autoclaved 
along with non-treated, deionized (control) water. The water solutions were distributed to the appropriate 
cages via glass bottles with rubber sips when the mice were 7 weeks old. For the remainder of the 
experiment, the water bottles and sips were changed weekly.  
Type 1 Diabetes Induction by Streptozotocin Injections. On 5 consecutive days, STZ was injected at 
40 mg/kg/day, intraperitoneally (i.p.), to control and SB-treated 8-week-old, male mice (Cetkovic-Cvrlje 
et al., 2017). Prior to injections each day, STZ was dissolved in 0.05 M citrate buffer (pH 4.5, Sigma-
Aldrich), vortexed, and within 30 minutes i.p. injected at 6.52 µl/g (ter Veld et al., 2008).  
Blood Glucose and Body Weight Measurements. At pre-decided time points, a lateral tail vein puncture 
was performed in a mouse to produce a small drop of blood that was then placed onto an Accu-Chek 
Aviva blood glucose meter strip to determine blood glucose levels. Glucose testing, along with body 
weight (g) measuring, was performed biweekly, starting 8 days after the initial STZ injection, until the 
experiment end. A mouse was considered diabetic after two consecutive readings of ≥ 250 mg glucose/dL 
(Cetkovic-Cvrlje et al., 2017). 
Euthanasia. At 12 weeks of age, mice were euthanized via CO2 asphyxiation. The mice were placed into 
an empty, clean 10-gallon plastic box. A stainless-steel lid was placed on top of the box, which is attached 
to the CO2 tank by flexible polyvinyl tubing. The CO2 tank was opened, allowing CO2 (at ≥ 200 psi) to 
fill the tank. The mice remained in the tank for at least 10 minutes; during this time, their heartbeats 
stopped, and the mice were considered deceased.  
Single Cell Suspension. Spleens were harvested from euthanized 12-week-old SB-treated and control 
mice and were smashed using a 10 cc syringe plunger and a 70 mm nylon mesh strainer with the addition 
of phosphate-buffered salt solution (PBS, Sigma-Aldrich). This process produced single (spleen) cell 
suspensions (SCS). The SCSs were put into a centrifuge and spun for 5 minutes at 1200 rpm 4°C. The 
supernatants decanted, and the pellets were resuspended in 0.75 ml of ACK lysing buffer (Lonza-
BioWhittaker) which was used to lyse the erythrocytes. The SCSs were washed three more times using 
PBS. A small portion of each SCS was mixed with Trypan blue (Lonza BioWhittaker), which stains dead 
cells blue. 20 µl of the mixtures were inserted into a hemocytometer for cell counting with a light 
microscope. Alive and dead cells were counted separately; this allowed for conclusions to be drawn, not 
only about how many cells there were in each sample, but also what percentage of those cells were living. 
This procedure has been described in more detail in the Cetkovic-Cvrlje et al. (1997) manuscript. 
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T-cell Proliferation. Proliferation assays were performed according to Cetkovic-Cvrlje et al. (2016). To 
summarize, splenocytes from SB-treated and control mice were suspended in complete media (CM), 
which contained RPMI-1640 medium, 1 U penicillin/ml, 100 µg streptomycin/ml and 10% fetal calf serum 
(FCS) (all purchased from Sigma-Aldrich). The CM-suspended cells were cultured in triplicates in a 96-
well-plate with and without the addition of 3 µg/ml Concanavalin A (ConA, Sigma-Aldrich) for 72 hours 
at 37°C and 5% CO2. ConA is T cell mitogen, which means it is used to induce proliferation (mitosis) of 
T cells (Dwyer & Johnson, 1981). After 72 hours, 10 µl of Alamar blue (Invitrogen), which is used to 
measure the reducing capacity of cells, was added to each well, and the plate was incubated for an 
additional 4-6 hours. Optical densities were then measured, at 570nm, with an ELISA plate reader 
(GeneMate).  
Immunophenotyping. Splenocytes were analyzed in order to detect particular types of immune cells 
(immunophenotypes) by flow cytometry (Cetkovic-Cvrlje et al., 2016). Aliquots of 106 splenocytes were 
obtained from the SCS of each mouse. Aliquots were spun down via centrifugation, the supernatants were 
decanted, and the pellets were resuspended in FACS buffer (0.1%NaN3, 1% FCS in PBS). Each sample 
was stained with a particular antibody mixture, incubated in the dark at 4°C for 45 minutes, washed, and 
analyzed using a FACSCalibur (BD Biosciences) flow cytometer. The antibodies against particular cell 
markers were purchased from BD Biosciences; these immune cell markers and their associated 
fluorochromes can be found in Table 1. A minimum of 10,000 cells were acquired for each analysis. 
Immunophenotype analysis was performed using CellQuest Prosoftware (BD Biosciences).  
Table 1. Cell types, cell markers, and antibody-associated fluorochromes, used for the flow cytometry. The 
fluorochrome column displays abbreviations of the following fluorochromes: peridinin chlorophyll-a protein 
(PerCP), fluorescein isothio-cyanate (FITC), allophycocyanin (APC), and phycoerythrin (PE). 
Cell Type Cell Marker Fluorochrome 
T cell (all types) CD3 PE 
T-cytotoxic  CD8 FITC 
T-helper  CD4 PerCP 
T-regulatory CD4 & CD25 APC 
B cell CD45RB220 APC 
Natural Killer Cell CD335 FITC 
Macrophage CD11b PerCP 
 
Statistical Analysis. For each of the statistical analyses, a p-value of < 0.05 was considered significant. 
Differences in diabetes incidence among experimental groups were determined using a life-table analysis, 
specifically looking at the log-rank test, using JMP Pro 14 statistical analysis software. For blood glucose 
levels and body weight data, Microsoft Excel was used to run a one-way analysis of variance with repeated 
measures, otherwise known as an ANOVA test. For immunophenotyping, T cell proliferation, cell counts, 
and cell viability a Student t test was performed using Microsoft Excel.  
Experimental Timeline. The mice were divided into two groups, control and treatment, and treatment 
began at 7 weeks of age (Day -7). Initial blood glucose and body weight measurements were also taken at 
that time. At 8 weeks of age (Day 0), STZ injections began. Between 9 and 12 weeks of age (Day 7 to 
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Day 28), blood glucose and body weight measurements were taken biweekly. At 12 weeks of age (Day 
30), all T cell-related experimental analyses were performed (SCS preparation, cell counting, the initiation 




Effect of Sodium Bicarbonate on the Development and Severity of T1D. To test the effect of SB 
treatment on the development and severity of T1D in a STZ-induced BL6 mouse model of disease, mice 
were treated with 200 mM SB from 7 to 12 weeks of age. One week after the initiation of treatment, each 
mouse, control and SB-treatment, received a daily low-dose of STZ for a period of 5 days to induce T1D. 
Prior to the induction to T1D (Day -7) there were no differences in glucose levels observed between the 
control and treatment groups (Figure 2). At 9 weeks of age, biweekly glucose measurements were taken 
until the end of the experiment (Day 7 to Day 28). As illustrated in Figure 1, 200 mM SB treatment 
significantly (p = 0.0444) decelerated T1D diabetes development and decreased diabetes incidence 
compared to control group. On Day 14, 47.6% of SB-treated mice were diabetes-free while only 14.3% 
of control mice were diabetes-free; at the end of experimental period, 33.3% of SB-treated mice were 
diabetes-free, while 9.5% of control mice were diabetes-free (Figure 1). 
Throughout the aforementioned time period, on average, the SB-treated group had lower blood glucose 




























Figure 2. Average blood glucose levels (mg/dL) +/- 
standard error of the mean (SEM) for 200 mM treatment 
vs control group of mice. No statistical significance was 
observed (p > 0.05). 
Figure 1. Incidence of diabetes in STZ-administered 
mice treated by 200 mM SB vs control group. 
Statistical significance was observed for incidence of 
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Sodium Bicarbonate and Immunotoxicity. The main focus of this project was to test SB’s potential in 
decreasing the incidence and severity of T1D, but it was also vital to observe whether a 200 mM dose of 
SB exhibited toxic effects. Thus, certain parameters were monitored in vivo and ex vivo. In vivo, an initial 
body weight measurement was collected for each mouse at 7 weeks of age (Day -7). Following 5 low 
doses of STZ given to induce T1D, body weight measurements were recorded biweekly (Day 7 to Day 
28) until the mice reached 12 weeks of age. During this time, there was no significant difference found 
between the 200 mM SB-treated group and the control group (p = 0.2706) (data not shown). A Trypan 
blue exclusion test was performed ex vivo after the preparation of the SCS. A small portion of the SCS 
was mixed with Trypan blue and splenocytes were counted. When comparing 200 mM SB-treated and 
control mice, there were no significant differences found in the context of total cell counts (p = 0.5288) 
(Figure 3), nor in the cell viability (p = 0.3681) (Figure 4). 
 
Effect of Sodium Bicarbonate on T cell Function. If SB had the potential to decrease the incidence and 
severity of T1D, which is a T cell mediated autoimmune disease, one would expect to observe SB-
mediated effects on T cell function. Thus, 
a T cell proliferation assay was 
performed. A portion of each SCS was 
plated with and without the addition of 
ConA and was stained with Alamar blue 
after the 3-day-culture period and was 
analyzed via spectrophotometry. When 
comparing T cell proliferation levels, in 
stimulated and non-stimulated 
conditions, there was no significant 
difference for non-stimulated (p = 
0.3614), as well as stimulated conditions 
(p = 0.6287) between the 200 mM SB-






















Figure 4. Splenic cell viability +/- standard error of the 
mean (SEM) for treatment vs control group of mice. No 






















Figure 3. Splenic cell counts (millions) +/- standard error 
of the mean (SEM) for treatment vs control group of mice. 
























Figure 5. Proliferation levels +/- standard error of the mean (SEM) 
for 200 mM treatment vs control group of mice. No statistical 
significance was observed (p > 0.05). 
 
6
Journal of Student Scholarship, Vol. 1 [2020], Iss. 1, Art. 6
https://repository.stcloudstate.edu/joss/vol1/iss1/6
Proceedings of the 9th Annual Minnesota State Conference of Undergraduate Scholarly and Creative Activity 
and 
St. Cloud State University Journal of Student Scholarship, Vol. 1, Special Issue 1, 2020 
 
 
SCSU JOSS 1(S1), 2020   
2020 MNSCUSCA Proceedings  61 
Effect of 200 mM Sodium Bicarbonate on Immune Cell Subpopulations. To shed light on SB’s 
mechanism of action in the context of immune cells, quantification of immune cell populations and 
subpopulations was performed. Thus, mouse 
splenocyte samples were stained with 
fluorochrome-labeled antibodies and a flow 
cytometer was used to quantify the immune cell 
types/subtypes. The percent of TC, TH, and Treg 
cells was slightly lower in the 200 mM SB-
treated mice compared to the control, while there 
was a trend of slight increase in the percent of B 
cells, natural killer (NK) cells, and macrophages 
in the SB-treated group. However, comparing 
the SB-treated against the control group, across 
all immune parameters, no significant 
differences were observed (Figure 6). The p-
values for the 200 mM SB-treated group versus 
the control group are as follows: CD3+ (p = 
0.4697), CD4+ (p = 0.3958), CD8+ (p = 0.4718), 
Treg (p = β0.4739), B cell (p = 0.4218), NK cells 
(p = 0.1696), and macrophages (p = 0.5460). The 
cell types that coincide with these cell markers 




This study showed for the first-time effects of SB treatment in an in vivo T1D mouse model. The results 
imply that SB has the potential to reduce the incidence and severity of the disease, as SB treatment 
significantly delayed the onset of disease, while simultaneously lowering glycemia levels. SB did not 
show toxic effects; this was confirmed with no changes in the body weights during the treatment period, 
as well as with intact splenic cell counts and viability. Interestingly, SB did not affect T cell function nor 
the frequency of T cell populations/subpopulations. Thus, further research into SB’s mechanism of action, 
in the context of T cells, needs to be performed. Cytokine secretion will be studied to elucidate how SB 
affects particular T cell subpopulations regardless of not affecting their numbers. Overall, whereas these 
results are not conclusive about the mechanism of action of SB in T1D, they serve as a promising first 
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Control (n=14) Treatment (n=13)
Figure 6. Spleen cell immunophenotypes +/- standard error 
of the mean (SEM) for 200 mM treatment vs control group 
of mice. No statistical significance was observed (p > 0.05). 
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